This module names a transducer: the cited review states that histamine's effect on the parietal cell is mediated by activation of adenylate cyclase and generation of cAMP, so GO:0007189 and GO:0006171 are bound on it. The sibling module h1_receptor_antagonism binds none, because no abstract cited there states the H1 receptor's coupling. The asymmetry is in the available sources, not in the two receptors' biology being differently well understood. The effector chain is graded INDIRECT on the Shamburek and Schubert review throughout: that review describes what histamine does at the receptor and what the antagonists are, not a measurement of the blocked state, so the step from occupancy to reduced secretion is an inference from the unblocked chain. The tolerance node is the exception and is DIRECT, because its source measured the diminishing antisecretory effect itself. Ranitidine is not bound among the therapeutic agents although the 1992 review names it as first-line, because NDMA contamination led to recalls and registration suspensions; that is a manufacturing and chemistry matter rather than a consequence of H2 blockade, so it is cited on the treatment and is not a pathograph node. Nizatidine is likewise unbound: CHEBI:7601 exists, so the omission is a deliberate silence rather than a missing lookup, but no source cited here establishes its current availability. The tolerance evidence carries its own negative half, quoted rather than dropped: duodenal ulcer patients do not develop significant tolerance on the sparse data available, so the node is scoped to the healthy-volunteer finding and to diseases needing tight acidity control, which is where the cited source puts it. Four entries bundle an H1 and an H2 antihistamine into a single treatment (Mast_Cell_Activation_Syndrome, with cetirizine and famotidine together; Maculopapular_Cutaneous_Mastocytosis; Systemic_Mastocytosis; and Monoclonal_Mast_Cell_Activation_Syndrome). Where the two agents are bound as separate agents, each receptor carries its own target_mechanisms link, and all four conform to the H1 module's occupancy node (h1_receptor_antagonism), which asserts nothing about the H2 agent beside it. The H2 side of those treatments is not yet represented by this module; whether it should be is a question of this module's scope (#15923), not a prerequisite for the H1 conformance.
By what mechanism does the antisecretory effect of an H2-receptor antagonist diminish on repeated dosing, and why do patients with duodenal ulcer disease appear not to show it?
KNOWLEDGE GAP
h2ra_tolerance_mechanism
Attached to:
Tolerance to the Antisecretory Effect on Repeated Dosing
The cited overview establishes that tolerance occurs and states outright that the mechanisms implicated in its development remain unclear. It is a genuine biological unknown rather than an uncurated fact: the measurements exist and agree that the effect diminishes, and no mechanism has been identified for it. It matters to this module because tolerance is the property that distinguishes this mechanism from proton-pump inhibition, and because the same source reports that duodenal ulcer patients do not develop significant tolerance -- so whatever the mechanism is, it is either absent or compensated in that group, which a candidate explanation has to account for. Receptor downregulation and the secondary hypergastrinemia that follows acid suppression are both available as hypotheses; neither is established by any source cited here, so neither is asserted as a node.
Proposed experiments:
Parallel receptor-density and gastrin time-course during H2 antagonist dosing in volunteers and duodenal ulcer patients
H2 Receptor Antagonist Occupancy
trigger
An H2-receptor antagonist binds the histamine H2 receptor on the gastric parietal cell and competes with histamine for it. The cited review classes the agents as competitive antagonists at a stimulatory receptor, which is the mechanistic claim this node makes: they occupy the receptor rather than inhibiting the terminal pump, and that is what separates the class from the proton-pump inhibitors and what makes the downstream chain surmountable by raised histamine drive.
Downstream
-
Loss of Histamine-Driven Adenylate Cyclase and cAMP Signalling in the Parietal Cell
-
Nocturnal Acid Breakthrough Addressed by Adding an H2 Antagonist to a Proton Pump Inhibitor
-
Central Nervous System, Cardiac and Endocrine Effects and Drug Interactions
Show evidence (1 reference)
"These include competitive antagonists that interact with stimulatory receptors (e.g., histamine H2-receptor antagonists)"
States the class's mechanism as competitive antagonism at a stimulatory receptor, which is what this node asserts and what distinguishes it from the pump inhibitors named in the same sentence.
Loss of Histamine-Driven Adenylate Cyclase and cAMP Signalling in the Parietal Cell
effector
Histamine's stimulatory effect on the parietal cell runs through activation of adenylate cyclase and generation of cAMP, so occupying H2 removes that second-messenger arm. The gastrin and acetylcholine inputs are not removed with it: they act through cytosolic calcium, which is why this node is a loss of one of three convergent inputs rather than a shutdown of parietal-cell stimulation, and why the acid suppression downstream is partial.
Downstream
-
Reduced H+/K+-ATPase-Mediated Gastric Acid Secretion
Show evidence (2 references)
"that of histamine is mediated by activation of adenylate cyclase and generation of cAMP"
Names the transducer this node binds. INDIRECT because the review states what histamine does at the receptor, so the claim that antagonism removes it is an inference from the unblocked chain rather than a measurement of the blocked one.
"The stimulatory effect of acetylcholine and gastrin is mediated by an increase in cytosolic calcium, whereas that of histamine is mediated by activation of adenylate cyclase and generation of cAMP."
Establishes that the calcium-mediated gastrin and acetylcholine inputs are separate from the cAMP arm, which is why this node is scoped to one of three convergent inputs.
Tolerance to the Antisecretory Effect on Repeated Dosing
adverse effect
The antisecretory effect diminishes with repeated oral dosing, which is established in healthy volunteers and is the class's characteristic limitation. The cited overview is careful about its scope and so is this node: patients with duodenal ulcer disease do not develop significant tolerance on the sparse data available, so the finding bears on diseases that need tight control of acidity rather than on ulcer healing. The mechanism is not known, which is recorded as a knowledge gap rather than filled in.
Show evidence (2 references)
"Diminution of antisecretory effect of H2-receptor antagonists with repeated oral dosing, termed tolerance, has been established in healthy volunteers."
The node's claim, measured rather than inferred, which is why this is the one DIRECT step in the chain. Graded HUMAN_CLINICAL because the finding it synthesises is a human volunteer measurement.
"Patients with duodenal ulcer disease, however, do not develop significant tolerance, according to the sparse investigations available."
The negative half of the same source, quoted so the node is not read as a general claim about every indication. It is what scopes tolerance to diseases needing tight acidity control.
Nocturnal Acid Breakthrough Addressed by Adding an H2 Antagonist to a Proton Pump Inhibitor
effector
In Helicobacter pylori-negative high-grade reflux disease with resistance to a proton pump inhibitor, intragastric pH may still fall overnight on the inhibitor, and adding an H2 antagonist can control that, at least over the short term. The population is the narrow one the cited review names and not patients on a proton pump inhibitor generally. The node is in this module because the mechanism is this module's: the H2RA removes the histamine arm upstream of the pump, which is a different point of attack from the pump inhibitor and so is not redundant with it. Its parent is the trigger rather than the acid-secretion effector, because the claim is about what adding the drug achieves in a patient already on another agent, not about a further reduction of the same node.
Show evidence (3 references)
"Some patients with Helicobacter pylori-negative high-grade GERD may show nocturnal decreases in pH during treatment with PPIs and resistance to treatment with PPI."
The sentence that carries this node's defining claim: that pH falls overnight on a proton pump inhibitor, and in which patients. It also fixes the node's population, which is narrower than patients on a proton pump inhibitor generally.
"addition of H2RAs to PPIs can be useful for controlling GERD, at least for short-term treatment"
The intervention half of the claim, with the source's own time limit kept in the quote rather than dropped. It does not by itself establish the nocturnal element, which the item above carries.
"PPIs have better characteristics for the long-term treatment of GERD, because they have a long-lasting, strong effect of raising intragastric pH and have no tachyphylaxis/tolerance phenomena on repeated dosing."
Context for why the add-on is short-term. INDIRECT and worth stating precisely: the sentence asserts the absence of tolerance for PPIs, and the implication that H2RAs show it is the contrast the sentence draws rather than something it states of H2RAs. PMID:1363254 is the direct source for that claim.
Central Nervous System, Cardiac and Endocrine Effects and Drug Interactions
adverse effect
The class is generally well tolerated, but the cited review records CNS, cardiac and endocrine effects, together with interference in the absorption, metabolism and elimination of other drugs. No mechanism is asserted for any of them: the review names the effects without stating how they arise, and the interaction effects in particular are a pharmacokinetic property of individual agents rather than a consequence of H2 blockade. The node hangs off the trigger because what is sourced is that taking these drugs produces these effects.
Show evidence (1 reference)
"histamine H2-receptor antagonists may cause untoward CNS, cardiac, and endocrine effects as well as interference with the absorption, metabolism, and elimination of various drugs"
Names the adverse groups this node carries. The review states them of the class without a mechanism, which is why none is asserted here and why the node's parent is drug occupancy rather than the acid-secretion effector.
H2 Receptor Antagonist Therapy
Platform:
Small molecule
Famotidine and cimetidine, given to suppress gastric acid secretion in peptic ulcer disease and reflux disease. Ranitidine, which the cited 1992 review lists alongside them as first-line, is not bound as an agent here: NDMA contamination of ranitidine products led to recalls and registration suspensions. That is a contaminant and manufacturing matter rather than a consequence of H2 blockade, so it is recorded here and not as a mechanism node.
Evidence: 2
H2 Receptor Antagonist Added to a Proton Pump Inhibitor for Nocturnal Acid Breakthrough
Platform:
Small molecule
An H2 antagonist given on top of a proton pump inhibitor, for the population the cited review names: Helicobacter pylori-negative high-grade reflux disease with resistance to the inhibitor, where intragastric pH still falls overnight on it. Kept separate from the monotherapy treatment because it is a different clinical decision with a different evidence base and an explicit short-term limit, and because bundling it would put two regimens behind one platform claim.
Evidence: 2